MENU
+Compare
LENZ
Stock ticker: NASDAQ
AS OF
Jul 25 closing price
Price
$31.62
Change
-$1.78 (-5.33%)
Capitalization
889.98M

LENZ LENZ Therapeutics Forecast, Technical & Fundamental Analysis

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products... Show more

LENZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for LENZ with price predictions
Jul 25, 2025

LENZ's Stochastic Oscillator stoops into oversold zone

The Stochastic Oscillator for LENZ moved into oversold territory on July 25, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LENZ advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 148 cases where LENZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for LENZ moved out of overbought territory on July 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on LENZ as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LENZ turned negative on July 22, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LENZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LENZ broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LENZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.636) is normal, around the industry mean (18.053). P/E Ratio (47.909) is within average values for comparable stocks, (59.920). LENZ's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.580). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (280.104).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LENZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
LENZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

LENZ is expected to report earnings to rise 71.70% to -91 cents per share on March 25

LENZ Therapeutics LENZ Stock Earnings Reports
Q4'23
Est.
$-0.91
Q1'25
Missed
by $0.06
Q4'24
Missed
by $0.36
Q3'23
Est.
$-0.24
Q2'23
Missed
by $5.82
The last earnings report on May 07 showed earnings per share of -52 cents, missing the estimate of -46 cents. With 253.18K shares outstanding, the current market capitalization sits at 889.98M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
445 Marine View Avenue
Phone
+1 858 925-7000
Employees
N/A
Web
https://www.lenz-tx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HAIBX32.18N/A
N/A
Hartford Balanced HLS IB
TVOAX37.86N/A
N/A
Touchstone Small Cap Value A
TRXCX12.06N/A
N/A
Catalyst/MAP Global Balanced C
VGINX88.78N/A
N/A
JPMorgan US Value R6
EMGEX8.00-0.05
-0.62%
Emerging Markets Equities Fund F-3

LENZ and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LENZ has been loosely correlated with BEAM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LENZ jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LENZ
1D Price
Change %
LENZ100%
-5.33%
BEAM - LENZ
46%
Loosely correlated
+3.68%
XNCR - LENZ
46%
Loosely correlated
N/A
CRNX - LENZ
46%
Loosely correlated
+1.91%
ZYME - LENZ
45%
Loosely correlated
-4.85%
ARWR - LENZ
45%
Loosely correlated
-3.20%
More